DFTX
Definium Therapeutics, Inc. NASDAQ Listed Nov 15, 2016$36.67
+49.80%
vs $24.48
Mkt Cap $3.3B
52w Low $6.49
100.0% of range
52w High $36.67
50d MA $22.91
200d MA $16.42
P/E (TTM)
-14.7x
EV/EBITDA
—
P/B
9.9x
Debt/Equity
0.0x
ROE
-55.3%
P/FCF
-24.9x
RSI (14)
81.10
ATR (14)
$1.76
Beta
2.56
50d MA
$22.91
200d MA
$16.42
Avg Volume
2.6M
Definium Therapeutics, Inc. is a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.
One World Trade Center · New York, NY 10007 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 7, 2026 | AMC | -0.49 | -0.71 | -44.3% | 23.20 | -1.5% | -5.0% | -2.9% | -1.1% | +4.0% | -3.0% | — |
| Feb 26, 2026 | AMC | -0.48 | -0.51 | -5.4% | 17.29 | -1.6% | +0.9% | -1.5% | +3.0% | +0.4% | -1.2% | — |
| Nov 6, 2025 | AMC | -0.52 | -0.78 | -50.0% | 11.34 | -3.4% | +3.2% | +0.4% | +6.2% | -2.7% | -4.2% | — |
| Jul 31, 2025 | AMC | -0.38 | -0.50 | -31.6% | 9.09 | -6.4% | -7.2% | +10.9% | +3.0% | +2.6% | +1.0% | — |
| May 8, 2025 | AMC | -0.36 | -0.35 | +2.8% | 6.46 | +0.0% | -4.8% | +4.9% | -1.2% | +2.7% | +0.2% | — |
| Mar 6, 2025 | AMC | -0.33 | -0.41 | -24.2% | 6.61 | -0.9% | +3.3% | -7.8% | +0.6% | +1.7% | -2.2% | — |
| Nov 7, 2024 | AMC | -0.29 | -0.27 | +6.9% | 7.52 | +2.3% | +12.9% | +5.7% | -8.7% | +2.6% | -0.1% | — |
| Aug 13, 2024 | AMC | -0.30 | -0.48 | -60.0% | 6.59 | +4.7% | +1.1% | -3.6% | -0.9% | +0.0% | -3.0% | — |
| May 8, 2024 | AMC | -0.66 | -0.60 | +9.1% | 9.61 | -2.9% | -5.1% | +1.5% | -8.7% | +0.5% | +6.8% | — |
| Feb 28, 2024 | AMC | -0.48 | -0.59 | -22.9% | 5.35 | +2.6% | +6.9% | +8.9% | +0.2% | -4.8% | +0.0% | — |
| Nov 2, 2023 | AMC | -0.65 | -0.53 | +18.5% | 2.70 | +2.2% | +14.4% | -5.5% | -3.4% | -4.6% | -5.6% | — |
| Aug 3, 2023 | AMC | -0.54 | -0.72 | -33.3% | 4.71 | -0.8% | -7.6% | -4.8% | +4.8% | -3.7% | +2.6% | — |
| May 4, 2023 | AMC | -0.41 | -0.51 | -24.4% | 3.62 | -2.5% | -5.8% | -0.6% | -2.9% | -2.4% | -3.7% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 22 | Leerink Partners | Maintains | Outperform → Outperform | — | $23.84 | $24.08 | +1.0% | -3.2% | +0.8% | -3.4% | -6.7% | +1.4% |
| Apr 16 | Canaccord Genuity | Maintains | Buy → Buy | — | $22.15 | $22.31 | +0.7% | +1.4% | +1.0% | +2.2% | +2.8% | -3.2% |
| Mar 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $17.45 | $16.76 | -4.0% | -1.5% | +3.0% | +0.4% | -1.2% | +0.6% |
| Jan 23 | RBC Capital | Maintains | Outperform → Outperform | — | $16.97 | $17.31 | +2.0% | +2.5% | -5.1% | +5.9% | -3.7% | +2.4% |
| Jan 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $22.80 | $22.50 | -1.3% | -2.6% | -11.5% | -4.6% | -1.6% | -3.3% |
No insider trades available.
8-K · 8.01
!! High
Definium Therapeutics, Inc. -- 8-K 8.01: Material Event / Announcement
Jun 22
8-K · 8.01
!! High
Definium Therapeutics, Inc. -- 8-K 8.01: Material Event / Announcement
May 19
8-K · 8.01
!! High
Definium Therapeutics, Inc. -- 8-K 8.01: Material Event / Announcement
Definium Therapeutics filed a material event announcement via press release, though the specific announcement details aren't disclosed in this 8-K filing summary alone.
May 12
8-K · 8.01
!! High
Definium Therapeutics, Inc. Common Shares -- 8-K 8.01: Material Event / Announcement
Definium Therapeutics shared its investor presentation from its April 2026 Analyst Day, potentially outlining clinical progress, pipeline updates, or financial guidance for stakeholders.
Apr 22
8-K
Definium Therapeutics, Inc. Common Shares -- 8-K Filing
Definium Therapeutics reported 2025 full-year financial results and business updates for its late-stage psychiatric and neurological disorder therapeutic programs.
Feb 26
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Avoro Capital Advisors Llc | 5,000,000 | $94M | New | Mar 2026 |
| 2 | Janus Henderson Group Plc | 3,556,041 | $67M | New | Mar 2026 |
| 3 | Fmr Llc | 1,809,610 | $34M | New | Mar 2026 |
| 4 | Trails Edge Capital Partners, Lp | 1,738,110 | $33M | New | Mar 2026 |
| 5 | Citadel Advisors Llc | 1,333,442 | $25M | New | Mar 2026 |
| 6 | Two Sigma Investments, Lp | 1,201,610 | $23M | New | Mar 2026 |
| 7 | Marshall Wace, Llp | 1,200,825 | $23M | Reduced | Mar 2026 |
| 8 | Vanguard Capital Management Llc | 1,096,978 | $21M | New | Mar 2026 |
| 9 | Vanguard Portfolio Management Llc | 872,665 | $16M | New | Mar 2026 |
| 10 | Millennium Management | 846,896 | $16M | New | Mar 2026 |
| 11 | Northern Trust Corp | 798,987 | $15M | New | Mar 2026 |
| 12 | Bank Of New York Mellon Corp | 752,922 | $14M | New | Mar 2026 |
| 13 | Woodline Partners Lp | 752,792 | $14M | New | Mar 2026 |
| 14 | Nuveen, Llc | 698,130 | $13M | New | Mar 2026 |
| 15 | Ensign Peak Advisors, Inc | 546,783 | $10M | Added | Mar 2026 |
| 16 | Ubs Group Ag | 493,977 | $9M | New | Mar 2026 |
| 17 | Qube Research & Technologies Ltd | 426,055 | $8M | New | Mar 2026 |
| 18 | Tri Locum Partners Lp | 369,588 | $7M | New | Mar 2026 |
| 19 | Superstring Capital Management Lp | 351,461 | $7M | New | Mar 2026 |
| 20 | Stempoint Capital Lp | 325,483 | $6M | New | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$3.28B
Enterprise Value
$2.86B
P/E (TTM)
-14.73x
Forward P/E
—
PEG Ratio
-0.19x
P/B
9.86x
P/S
—
P/FCF
-24.90x
EV/EBITDA
—
Shares Out
89.3M
Financials (TTM)
Revenue
$0
Net Income
-$237.5M
EBITDA
-$222.4M
Free Cash Flow
-$131.6M
Op Cash Flow
-$131.6M
EPS Basic
$-2.06
EPS Diluted
$-2.49
EPS Forward
$-2.00
Gross Margin
—
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$440.1M
Total Liab.
$107.8M
Total Equity
$332.3M
Cash
$411.6M
LT Debt
$0
Book Value/Sh
$3.72
Debt/Equity
0.00x
Current Ratio
6.29
Quick Ratio
6.29
Returns & Growth
ROE
-55.3%
ROA
-41.8%
ROIC
-44.5%
Rev Growth YoY
+0.0%
EPS Growth YoY
-33.8%
Price Returns
2W
+13.3%
1M
+10.6%
3M
+38.6%
6M
+91.2%
12M
+233.2%
Technicals
52W High
$36.67
52W Low
$6.49
50d MA
$22.91
200d MA
$16.42
RSI (14)
81.10
ATR (14)
$1.76
Beta
2.56
Avg Volume
2.6M
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$35.63
High
$49.00
Low
$25.00
Median
$36.50
Data updated apr 25, 2026 5:03am
· Source: financialmodelingprep.com